{"id":11154,"date":"2022-08-25T00:00:00","date_gmt":"2022-08-25T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/"},"modified":"2025-08-19T08:28:14","modified_gmt":"2025-08-19T13:28:14","slug":"fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/","title":{"rendered":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire"},"content":{"rendered":"<p>The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.<\/p>\n<p><strong><a href=\"https:\/\/www.onclive.com\/view\/fda-grants-breakthrough-therapy-designation-to-talquetamab-for-relapsed-refractory-myeloma\" target=\"_blank\" rel=\"noopener\">Lire la suite ici<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11154","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2022-08-25T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:14+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#blogposting\",\"name\":\"FDA accorde la d\\u00e9signation de traitement r\\u00e9volutionnaire au talquetamab pour le my\\u00e9lome r\\u00e9cidivant\\\/r\\u00e9fractaire | My\\u00e9lome Canada\",\"headline\":\"FDA accorde la d\\u00e9signation de traitement r\\u00e9volutionnaire au talquetamab pour le my\\u00e9lome r\\u00e9cidivant\\\/r\\u00e9fractaire\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2022-08-25T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:14-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#listItem\",\"name\":\"FDA accorde la d\\u00e9signation de traitement r\\u00e9volutionnaire au talquetamab pour le my\\u00e9lome r\\u00e9cidivant\\\/r\\u00e9fractaire\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#listItem\",\"position\":4,\"name\":\"FDA accorde la d\\u00e9signation de traitement r\\u00e9volutionnaire au talquetamab pour le my\\u00e9lome r\\u00e9cidivant\\\/r\\u00e9fractaire\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/\",\"name\":\"FDA accorde la d\\u00e9signation de traitement r\\u00e9volutionnaire au talquetamab pour le my\\u00e9lome r\\u00e9cidivant\\\/r\\u00e9fractaire | My\\u00e9lome Canada\",\"description\":\"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2022\\\/08\\\/25\\\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2022-08-25T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:14-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada","description":"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.","canonical_url":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#blogposting","name":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada","headline":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2022-08-25T00:00:00-05:00","dateModified":"2025-08-19T08:28:14-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#listItem","name":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#listItem","position":4,"name":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/","name":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada","description":"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2022-08-25T00:00:00-05:00","dateModified":"2025-08-19T08:28:14-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada","og:description":"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici.","og:url":"https:\/\/myeloma.ca\/fr\/2022\/08\/25\/fda-accorde-la-designation-de-traitement-revolutionnaire-au-talquetamab-pour-le-myelome-recidivant-refractaire\/","article:published_time":"2022-08-25T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:14+00:00","twitter:card":"summary_large_image","twitter:title":"FDA accorde la d\u00e9signation de traitement r\u00e9volutionnaire au talquetamab pour le my\u00e9lome r\u00e9cidivant\/r\u00e9fractaire | My\u00e9lome Canada","twitter:description":"The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody. Lire la suite ici."},"aioseo_meta_data":{"post_id":"11154","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 16:03:35","updated":"2026-04-30 07:13:22","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11154"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154\/revisions"}],"predecessor-version":[{"id":31283,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11154\/revisions\/31283"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}